Processa Ev To Sales from 2010 to 2024
| PCSA Stock | USD 1.02 0.04 4.08% |
EV To Sales | First Reported 2010-12-31 | Previous Quarter 785.41 | Current Value 824.68 | Quarterly Volatility 388.21537904 |
Check Processa Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Processa Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 115.6 K, Selling General Administrative of 5.9 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 665, Dividend Yield of 0.0 or PTB Ratio of 1.67. Processa financial statements analysis is a perfect complement when working with Processa Pharmaceuticals Valuation or Volatility modules.
Processa | Ev To Sales |
Latest Processa Pharmaceuticals' Ev To Sales Growth Pattern
Below is the plot of the Ev To Sales of Processa Pharmaceuticals over the last few years. It is the Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue. Processa Pharmaceuticals' EV To Sales historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Processa Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Ev To Sales | 10 Years Trend |
|
Ev To Sales |
| Timeline |
Processa Ev To Sales Regression Statistics
| Arithmetic Mean | 604.77 | |
| Geometric Mean | 373.84 | |
| Coefficient Of Variation | 64.19 | |
| Mean Deviation | 351.48 | |
| Median | 872.68 | |
| Standard Deviation | 388.22 | |
| Sample Variance | 150,711 | |
| Range | 923 | |
| R-Value | 0.62 | |
| Mean Square Error | 99,718 | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | 53.91 | |
| Total Sum of Squares | 2.1M |
Processa Ev To Sales History
About Processa Pharmaceuticals Financial Statements
Processa Pharmaceuticals stakeholders use historical fundamental indicators, such as Processa Pharmaceuticals' Ev To Sales, to determine how well the company is positioned to perform in the future. Although Processa Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Processa Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Processa Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Processa Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EV To Sales | 785.41 | 824.68 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Processa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Processa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Processa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Processa Pharmaceuticals Stock:Check out the analysis of Processa Pharmaceuticals Correlation against competitors. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.80) | Return On Assets (1.13) | Return On Equity (2.12) |
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.